VAP Diagnostics Lab
James McClintic has extensive work experience in various leadership roles within the medical and laboratory industry. James currently serves as a Clinical Laboratory Consultant at McClintic Group LLP, a role they have held since 2017. Prior to this, they were the President and CEO of Atherotech from 2014 onwards. In 2009, they became the Managing Partner of SpringFire Laboratory Network LLC and also held the same position at The McClintic Busa Group, LLP until 2010. James McClintic has also served as the CEO of Exagen Diagnostics from 2005 to 2008 and of Esoterix from 1999 to 2005. Prior to that, they were the Eastern Regional President at Corning Clinical Laboratories from 1994 to 1996. Additionally, they served as CEO at Scicor from 1991 to 1994 and held various positions at E.R. Squibb and Sons, including Vice President of Marketing Planning from 1975 to 1991.
James McClintic attended San Diego State University from 1960 to 1969, where they obtained a Bachelor of Science degree in Marketing.
This person is not in any teams
This person is not in any offices
VAP Diagnostics Lab
VAP Diagnostics Lab is a clinical reference laboratory focusing on cardiometabolic health and disease management solutions. Our proprietary test, the VAP+ Lipid Panel, provides a direct measurement of the comprehensive lipid profile by using a patented density gradient ultracentrifugation. VAP Diagnostics provides its unique testing services to physicians, hospitals, clinics, and other laboratories throughout the United States. About The VAP+ Lipid Panel The VAP+ Lipid Panel is an expanded cholesterol profile that provides direct, detailed measurements of cholesterol, or lipid, subclasses, which play important roles in the development of cardiovascular disease, the No. 1 cause of death in the United States. The test identifies a far greater number of people at risk for heart disease than traditional cholesterol tests developed in the 1970s. Measurements obtained using The VAP+ also provide doctors with a foundation from which to develop individualized treatment plans while continuing to track patients' progress in battling heart disease. The price of the VAP+ is comparable to the traditional cholesterol test.